The approval being sought from the US Food and Drug Administration (FDA) is for the post-surgery use of Kadcyla in patients with HER2-positive early breast cancer with residual
The post Roche seeks FDA approval for Kadcyla in HER2-positive early breast cancer appeared first on Pharmaceutical Business review.